Dr. Emens Discusses Overall Survival in HER2+ Breast Cancer

Video

Dr. Leisha Emens of the University of Pittsburgh Medical Center's Hillman Cancer Center discusses the overall survival in the KATE2 study.

We spoke with Dr. Leisha Emens, PhD, at the European Society for Medical Oncology Congress 2019, held in Barcelona, Spain from September 27, 2019 to October 1, 2019. Dr. Emens shared her thoughts on overall survival in the phase II KATE2 study. KATE2 is the study of the PDL-1 inhibitor atezolizumab (Tecentriq) and T-DM1(Kadcyla) vs a placebo and T-DM1 in previously treated HER2-positive advanced breast cancer.

 

Transcript:

"Currently, there is a large effort to develop effective immunotherapy combinations that can enhance the activity of single agent PD-1 or PDL-1 blockade. HER2-positive breast cancer is unique in that there are a number of HER2-targeted agents that could potentially be combined with immune checkpoint blockade. The main ones include trastuzamab and trastuzamab emtansine, an antibody-drug conjugate. Both of those have, as a backbone, the trastuzamab antibody which in and of itself has immune-modulating activity. The antibody drug conjugate also has a chemotherapeutic agent conjugated directly to the antibody and that could also potentially have immune-modulating activity.

So, the rationale underlining KATE2, which is a phase II randomized trial that explored the clinical activity of adding atezolizumab to TDM1, is that combining these 2 agents maybe additive or even synergistic relative to the clinical activity of the single agents alone."

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content